Summary
PROJECT SUMMARY / ABSTRACT As with many other diseases, Alzheimer’s disease (AD) is a multifactorial disorder consisting of multiple pathologies that are each known to be deleterious in their own right. Clinical trials assessing disease-modifying drugs for Alzheimer’s disease (AD) have largely been focused on amyloid beta (Aβ) pathology rather than other pathological components including tau pathology and gliosis. This is in part due to Aβ pathology being viewed as the initiating event responsible for all other pathologies. The interim result is Aducanumab (AduhelmTM; Biogen) recently approved
